

Receipt date: 05/12/2009

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10510411 - GALL 1644

Form 1644 (2008)

Approved for use through 01/31/2009 OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Not for submission under 37 CFR 1.99)

Application Number	10510411
Filing Date	2005-09-12
First Named Inventor	Habib Zaghouani et al.
Art Unit	1644
Examiner Name	Gerald R. Ewoldt
Attorney Docket Number	119742-002

U.S.PATENTS**Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add**U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button

Add**FOREIGN PATENT DOCUMENTS****Remove**

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	9932136	WO		1999-07-01	Alexion Pharmaceuticals, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add**NON-PATENT LITERATURE DOCUMENTS****Remove**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

2005-09-12

Habib Zaghouani et al.

1644

Gerald R. Ewoldt

119742-002

1 Atkinson, Mark A. et al., the NOD Mouse Model of Type 1 Nature Medicine. June 1999. 5(6):601-604.

2 Boltard, C., et al., Peripherin: An islet antigen that is cross-reactive with nonobese diabetic mouse class II gene products. Jan. 1992. Proc. Natl. Acad. Sci. 89:172-176.

3 Gregg, R. et al. Modulation of diabetogenic T cells by an Ig-chimera expressing insulin B 9-12. 2000. Faseb Journal & Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society, Seattle Washington, May 12-16, 2000. 14(6):A1218.

4 Gregg, R. et al. A plausible multi-modal strategy for effective suppression of diabetes. 2002. Faseb Journal, Bethesda, US, 22 March 2002. pp. A1043.

5 Johnson, G.G., et al. 1999. Anti-CD43 Monoclonal antibody L11 Blocks Migration of T Cells to Inflamed Pancreatic Islets and Prevents Development of Diabetes in Nonobese Diabetic Mice. The Journal of Immunology. 163:5678-5685.

6 Kürschner, C. et al. 1992. "IFN-gamma receptor-ig fusion proteins half-life, immunogenicity, and in vivo activity." Journal of Immunology, The Williams and Wilkins Co., Baltimore, vol. 149, no. 12, 15 December 1992. pp.4096-4100

7 Lenschow D.J. et al. 1992. "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4LG." Science, Washington, D.C., vol. 257, no. 5071, 7 August 1992. pp. 789-792.

8 Skyler, J.S. et al.. 2005. "Effects of oral insulin in relatives with type1 diabetes. Diabetes Care. 28(5):1068-1076.

9 Zheng, X. et al. 1999. "IL-2 receptor-targeted cytolytic IL-2/Fx fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice." Journal of Immunology, the Williams nad Wilkins Co., Baltimore, vol. 163, no. 7, 1 October 1999. pp. 4041-4048.

10

Receipt date: 05/12/2009

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10510411	10510411 - GAU: 1644
Filing Date	2005-09-12	
First Named Inventor	Habib Zaghouani et al.	
Art Unit	1644	
Examiner Name	Gerald R. Ewoldt	
Attorney Docket Number	119742-002	

12

Sutterwala, F.S. et al. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcg receptor type I. *J. Exp. Med.* 188:217-222.

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Gerald Ewoldt/	Date Considered	07/18/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.